The Codon Adaptation Index (CAI) is the most widespread technique for analyzing Codon usage bias. As opposed to other measures of codon usage bias, such as the ‘effective number of […]
All posts by signagen - 32. page
Codon usage bias
Codon usage bias refers to differences in the frequency of occurrence of synonymous codons in coding DNA. A codon is a series of three nucleotides (a triplet) that encodes a […]
How to optimize a synthetic gene for a specific specie
Refer to https://www.idtdna.com/CodonOpt
Managing MicroRNAs with Vector-Encoded Decoy-Type Inhibitors
A rapidly growing understanding of the complex circuitry of microRNA (miRNA)-mediated gene regulation is attracting attention to miRNAs as new drug targets. Targeted miRNA suppression is achieved in a sequence-specific […]
Going viral: chimeric antigen receptor T-cell therapy for hematological malignancies.
On July 1, 2014, the United States Food and Drug Administration granted ‘breakthrough therapy’ designation to CTL019, the anti-CD19 chimeric antigen receptor T-cell therapy developed at the University of Pennsylvania. […]
The CAR T-Cell Race
Tumor-targeting T-cell therapies are generating remarkable remissions in hard-to-beat cancers—and attracting millions of dollars of investment along the way. By Vicki Brower | April 1, 2015 BUILDING A BETTER T-CELL: […]
First Success With CAR T-Cells in a Solid Tumor
Chimeric antigen-receptor (CAR) T-cell therapy has repeatedly provided dramatic results in patients with hematologic malignancies. Now comes the first success story of CAR T-cell therapy in a solid tumor — […]
CAR T-CELL BIOTECH IPOs
Company Date Value Kite Pharma June 2014 $134.1 million Bellicum December 2014 $160 million Juno December 2014 $264.6 million Cellectis March 2015 $228 million
CAR T-CELL DEALS
Institution/Company Date Partner Terms University of Pennsylvania August 2012 Novartis Undisclosed Celgene March 2013 Bluebird Bio, Baylor College of Medicine Unspecified upfront payment plus up to $225 million per product […]